Microbial Fermentation Technology Market Analysis

Application (Antibiotics, Probiotics Supplements, Monoclonal Antibodies, Recombinant Proteins, Biosimilars, Vaccines, Enzymes, Small Molecules)

The antibiotics segment in the microbial fermentation technology market is estimated to gain a robust revenue share of 33% in the coming years owing to the rising consumption of antibiotics as they have had enormous success in improving health outcomes Moreover, it is expected that increasing personal incomes, and health insurance have driven the consumption of antibiotics across the globe. Antibiotics, the most significant category of bioactive chemicals, can be produced using microbiology through the fermentation method, in which the source microbe is cultured in big containers holding a liquid growth medium. 

For instance, Penicillin is an antibiotic used to treat infections in the mouth, throat, gums, and respiratory tract, and urine is created by the fermentation process. It is manufactured in a fermenter that is incubated at around 25oC to 26oC for approximately 5 to 7 days at pH 7 to 7.4 and can be mass-produced through the use of deep-tank batch fermentation. The demand for biopharma products is expanding in several nations owing to rising health concerns and advancements in biotechnology are expected to create profitable possibilities during the forecast period. According to estimates, antibiotic usage is expected to rise by more than 150% globally between 2015 and 2030.

Besides this, the recombinant proteins are poised to gain a notable share by the year 2036. Recombinant proteins are proteins that are encoded by recombinant DNA that facilitates gene expression and messenger RNA translation and are proteins that are generated artificially by inserting certain genes into host organisms such as bacteria or yeast.

End-User (Bio-Pharmaceutical Companies, Contract Research Organizations (CROs), CMOs & CDMOs, Academic & Research Institutes)

The biopharmaceutical companies segment in the microbial fermentation technology market is set to garner a notable share shortly on account of the rising need for biopharmaceutical products. Biopharma products such as enzymes, vaccines, antibiotics, and monoclonal antibiotics are in high demand which is expected to create a huge demand for microbial fermentation technology during the projection period. Moreover, biopharmaceuticals are mostly recombinant therapeutic proteins the production of which, employs a variety of procedures including fermentation that are thought to be crucial in their production. Additionally, many biopharmaceutical and biological products rely on (various) cell-type fermentation where microorganisms such as bacteria, yeast, and molds are increasingly being employed to produce biopharmaceuticals such as vaccines, recombinant proteins, antibiotics, and active pharmaceutical ingredients (APIs).

Furthermore, the CMOs & CDMOs are expected to hold a significant share during the forecast timeframe. CMOs and CDMOs are quickly becoming the preferred choice for biotherapeutics as they can produce industrial enzymes through fermentation. For instance, it is estimated that over 25% of biologics are manufactured by CDMOs/CMOs.

Our in-depth analysis of the global microbial fermentation technology market includes the following segments: